References

Chinese Acute Stroke Collaborative Group. (CAST) Chinese Acute Stroke Collaborative Group: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997;349:1641-7.

Chipperfield B, Chipperfield JR. Heart muscle magnesium, potassium and sinc concentrations after sudden death for heart disease. Lancet 1973;ii:293-6

Choussat R, Montalescot G. Blocking platelets more: are we scating on thin ice? Heart 1998;79:5-6.

Clarke R, Collins R. Can dietary supplements with folic acid reduce cardiovascular risk? J Cardiovascular Riak 1998;5:249.

Clarke RJ, Mayo G, Price P, Fitzgerald GA. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled release aspirin. NEJM 1991;325:1137-41.

Col NF, Yasrzbski J, Gore JM, Alpert JS, Goldberg RJ. Does aspirin consumption affect the presentation or severity of acute myocardial infarction? Arch Int Med 1995;155:1386-9

Collins R, Peto R, MacMahon S, Herbert P et al. Blood pressure, stroke and coronary disease. Lancet 1990;335:827-38.

Dabaghi SF, Kamat SG, Payne J et al. Effects of low-dose aspirin on in-vitro p[latelet agtgregation in the early minutes after injestion in normal subjects. Am J Cardiol 1994;74:720-3.

Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997;350:430-6.

Davies MJ, Thomas A. Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death. N Engl J Med 1984;310:1137-1140.

Dewood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902.

Doll and Peto Lancet 1997;315:1090

Doll R, Peto R, Hall E, Wheatley K, Gray R. Mortality in relation to consumption of alcohol: 13 years observations on male British doctors. BMJ 1994;309:911-8.

Donné A. De l'origine des globules du sang, de leur mode de formation et de leur fin. Compt. Rend. Acad. Sc. 1842;14:366-8.

Dreyfus F, Zahavi J. Adenosine diphosphate induced platelet aggregation in myocardial infarction and ischemic heart disease. Atheroslcerosis 1973;17:107-120.

DTB. Clopidogrel and Ticlopidine _ improvements on aspirin? Drugs and Therapeutic Bulletin 1999:37:59-61.

Ebrahim S, Smith GD. Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronaqry heart disease. BMJ 1997;314:1666-74

Editorial. The aspirin papers. Brit.Med.J. 1994;308:71-2.

Elwood PC Daily, weekly and seasonal variations in cardiovascular risk factors. Lipid Review 1995;9:6-8.

Elwood PC, Renaud S, Beswick AD, O'Brien JR, Sweetnam PM. Platelet aggregation and incident cardiovascular disease in the Caerphilly cohort. Heart 1998;80:578-582

Elwood PC, Beswick AD, O'Brien JR, Yarnell JWG, Layzell JC, Limb ES. Inter-relationships between haemostatic tests and the effects of some dietary determinants in the Caerphilly cohort of older men. Blood Coagulation and Fibrinolysis 1993;4:529-536.

Elwood PC, Cochrane AL, Burr M et al. A randomised controlled trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction. BMJ 1974;I:436-40

Elwood PC, Fehily AM, Poor DJ, Pickering J, Kamel F. Dietary magnesium does not predict ischaemic heart disease in the Caerphilly cohort. European Journal of Clinical Nutrition 1996;50:694-7

Elwood PC, Hughes C, O'Brien JR. Platelets, aspirin and cardiovascular disease. Postgraduate Med J. 1998;74:587-91

Elwood PC, Sweetnam PM, Beasley WH, Jones D, France R. Magnesium and calcium in the myocardium: cause of death and area differences. Lancet 1980;ii:720-2

Elwood PC. Gastric safety and enteric coated aspirin. Lancet 1997;349:432.

Ferner RE, Neil HAW. A suitable case for treatment. Lancet 1995;345:1051.

Fitzgerald DJ, Catella F, Roy L et al. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988;77:142-150.

Folts J. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation 1991;83:IV3-14.

Frankel S, Elwood P, Sweetnam P, Yarnell J, Davey Smith G. Birthweight, body-mass index in middle age, and incident coronary heart disease. Lancet 1996;348:1478-1480.

Garcia-Dorado D, Therous P, Tornos P et al. Previous aspirin use may attenuate the severity of the manifestation of acute ischaemic syndromes. Circulation 1995;92:1743-8

Ginj J van. Low doses of aspirin in stroke prevention. Lancet 1999;353:2172-3

Giovannucci E, Egan KM, Hunter D et al. aspirin and the risk of colorectal cancer. N.Eng.J.Med. 1995;333:655-7.

Glynn RJ, Buring JE, Manson JE et al. Adherence to aspirin in the prevention of myocardial infarction: The Physicians Health Study. Arch Intern Med 1994;154:2649-57.

Greenberg ER, Baron JA, Freeman DH jnr. Reduced risk of large-bowel adenomas among aspirin users. The polyp prevention study group. Nat.Cancer Instiy. 1993;85:912-6.

Gupta SK, Joshi S. Relationship between aldose reductase inhibiting activity and anticataract action of various non-steroidal anti-inflammatory drugs. in Sasaki K, Hockwin O (eds) Distribution of cataracts in the population and influencing factors and developments in ophthalmology. Basl, Karger, 1991.

Haerem JW. Platelet aggregates and mural micro-thrombi in the early stages of acute fatal coronary disease. Thromb Res 1974;5:243-249.

Hart LC, Davey Smith G, Hole DJ, Hawthorne VM. Alcohol consumption and mortality from all causes, coronary heart disease and stroke: results from a prospective cohort study of Scottish men with 21 years of follow-up. BMJ 1999;318: 1725-9.

Hass WK, Easton JD, Adams et al. An RCT comparing Ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. NEJM 1989;321:501-7

ISIS-4 A randomised factorial trial assessing oral captopril, oral mononitrate and intravenous magnesium sulphate in 58,050 patients with suspected myocardial infarction. Lancet 1995;345:669-85.

Juul-Moller S, Edvardsson N, Jahnmatz B et al. Double blind trial of Aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992;340:1421-5.

Khaw KT. Healthy ageing. BMJ 1997;315:1090-6.

Kmietowicz Z. aspirin benefits patients with stroke - but only just. Brit.Med.J. 1997;314:1646.

McCallumAK, Whincup PH, Morris RW, Thomson A, Walker M, Ebrahim S. aspirin use in middle-aged men with cardiovascular disease: are opportunities being missed? British Journal of General Practice 1997;47:417-21

McCormick J, Scrabnek P. Coronary heart disease is not preventable by population interventions. Lancet 1988;ii:839-41

McGeer PL, Schulzer M, McGeer EG. Arthritis and inti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies. Neurology 1996;47:425-32.

Meyer JS, Rogers RL, McClintic K et al. A randomised clinical trial of daily aspirin in multi-infarct dementia. A pilot study. J.Am.Geriat.Soc. 1989;37:549-55.

Minerva BMJ 1999;319:392.

Moher M, Johnson N. Use of aspirin by general practitioners in suspected acute myocardial infarction. BMJ 1995;308:760.

Moher M. Moher D. Havelock P. Survey of whether general practitioners carry aspirin in their doctor's bag. BMJ 1994; 308:761-2.

Molonet BA. An analysis of the side-effects of ticlopidine. In Hass WK and Easton JD (eds): Ticlopide, platelets and vascular disease. NY, Springer-Verlag. 1993.

Morgan G. Beneficial effects of NSAIDs in the gastrointestinal tract. European J of Gastroenterology and Hepatology 1999;11:393-400

Morgan G. Aspirin and Cancer. University of Wales 1998 ISBN 1 899717 20 X

Morris CDW. Acetylsalicylic acid and platelet stickiness. Lancet 1967;1:279-80.

MRC 1998. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:233-41

MRC Press release: Life-saving aspirin. January 7 1994.

MRC. MRC trial of treatment of mild hypertension: principal results. BMJ 1985;291:97-104

Muir N, Nichols JD, Clifford JM, Stillings MR, Hoare RC. The influence of dosing form on aspirin kinetics: implications for acute cardiovascular use. Curr Med Opinion 1997b;13:547-53.

Muir N, Nichols JD, Stillings MR, Sykes J. Comparative bioavailability of aspirin and paracetamol following single dose administration of soluble and plain tablets. Curr Med Res Opinion 1997a;13:491-500.

NHS Executive: The health of the nation: assessing the options: CHD/Stroke. Target effectiveness and cost-effectiveness of interventions to reduce coronary heart disease and stroke mortality. Department of Health 1995

Norfolk Health: East Norfolk Health Commission. Guidelines for practice procedure with a suspected heart attack. 1996.

O'Brien JR. Platelet aggregation Part II Some results from a new method of study. J.Clin.Path. 1962;15:452-5.

O'Brien JR Effects of salicylates on human platelets. Lancet 1968;i:779-83.

O'Brien JR aspirin and platelet aggregation. Lancet 1968;i:204-5.

O'Keefe JH, Lavie CJ, McCallister BD. Insights into the pathogenesis and prevention of coronary artery disease. Mayo Clin Proc. 1995;70:68-79

Osler W An account of certain organisms occurring in the liquour sanguinis Proc.R.Soc.Lond. 1874;22:391-462.

Patterson et al. J Clin Path 1998;51:502-5

Peto R, Gray R, Collins R et al. Randomised trial of prophylactic daily aspirin in British male doctors. Brit.Med.J. 1988;296:313-6.

Pierpoint WS. The natural history of salicylic acid, plant product and mammalian medicine. Interdisciplinary Science Reviews 19976;22:45-52.

Poikolainen K. Alcohol and mortality: a review. J Clin Epidemiol. 1995;48:455-65.

Rappaport E, Gheorhoriade M. Pharmacologic therapies after MI. Amer J Med 1996;101:4A61S-69S

The Platelet Receptor Inhibition in Ischaekic Syndrome Management Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable aspirin. NEJM 1998;338:1498-505

Ravenov U. Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome. BMJ 1992;305:15-

Rees MM Rogers GM. Homocysteinaeimia _ association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 1993;71:337-59.

Renaud S, de Lorgeril M. Wine, alcohol, platelets and the French paradox for coronary heart disease. Lancet 1992;339:1523-26

Renaud SC, Beswick AD, Fehily AM, Sharp DS, Elwood PC. Alcohol and platelet aggregation: the Caerphilly prospective heart disease study. Am J Clin Nutr 1992;55:1012-1017.

Richards M, Meade TW, Peart S, Brennan PJ, Mann AH. Is there any evidence for a protective effect of antithrombotic medication on cognitive function in men at risk of cardiovascular disease? J Neurology and Psychiatry. 1997;62:269-72.

Ridker PM, Manson JE, Buring JE, Muller JE, Hennekens CH. Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomised trial of physicians. Circulation 1990;82:897-902